Open Access Open Access  Restricted Access Subscription or Fee Access

Prevalence of Adverse Drug Reactions and Risk Factors Associated with first Line Anti- Tuberculosis Drugs

Miyanda Petty, Eric Sikaone

Abstract


Background: The recommended first line treatment of active tuberculosis (TB) consists of rifampicin (R), isoniazid (H), ethambutol (E) and pyrazinamide (Z). The regimen is highly effective in treating active TB however it is associated with various adverse drug reactions (ADRs) posing undeniable challenges to therapy success. Objectives: To determine the prevalence of ADRs and risk factors associated with first-line anti-tuberculosis medications. Methods: A quantitative cross-sectional descriptive study conducted at the University Teaching Hospital (UTH) during the period of 1st January, 2017 to 31st December, 2018. Results: A total of 180 patients on first line anti -TB drugs were recruited. The prevalence of ADRs was 18.3%. There were predominant male cases of tuberculosis (53%) and males had higher incidence of ADRs compared to females (58%). Increasing age had a significant relationship with occurrence of ADRs in first line drugs of Tuberculosis with a P value < 0.05. Alcohol intake and HIV /TB comorbid positively contributed to occurrence of ADRs. The commonly experienced ADRs were peripheral neuritis, hepatotoxicity, visual disturbances and cutaneous reactions. Conclusion: Most participants in this study had limited knowledge on adverse drug reactions and this could simply mean that some ADRs were unreported. Some factors found to be associated with occurrence of ADRs were HIV seropositive status, age, male gender and alcohol intake necessitating for close monitoring of patients with predisposing factors. Routine and intensive patient counselling, identification and treatment of ADRs is essential. Workshops on antitubercular ADRs sensitization for medical personnel should be conducted more often.


Keywords


Adverse drug reactions, Anti-TB drugs, prevalence, tuberculosis, HIV/AIDS.

Full Text:

PDF

References


Chung, Soo Jie, Sun-ju Byeon, and Jeong-Hee Choi. “Analysis of Adverse Drug Reactions to First-Line Anti-Tuberculosis Drugs Using the Korea Adverse Event Reporting System.” Journal of Korean medical science 37.16 (2022).

El Hamdouni, Mariam, et al. “Incidence of adverse reactions caused by first-line anti-tuberculosis drugs and treatment outcome of pulmonary tuberculosis patients in Morocco.” Infection 48.1(2020): 43–50.

Rich, Michael, and Ernesto Jaramillo. Guidelines for the programmatic management of drug-resistant tuberculosis. World Health Organization, 2008.

World Health Organization. Global tuberculosis report 2013. World Health Organization, 2013.

Imam, Faisal, et al. “Adverse drug reaction prevalence and mechanisms of action of first-line anti-tubercular drugs.” Saudi Pharmaceutical Journal 28.3 (2020): 316–324.

Chung-Delgado, Kocfa, et al. “Factors associated with anti-tuberculosis medication adverse effects:a case-control study in Lima, Peru.” PloS one 6.11 (2011): e27610.

Jassal, Mandeep, and William R. Bishai. “Extensively drug-resistant tuberculosis.” The Lancet infectious diseases 9.1 (2009): 19–30.

Prasad, Rajendra, Abhijeet Singh, and Nikhil Gupta. “Adverse drug reactions in tuberculosis and management.” indian journal of tuberculosis 66.4 (2019): 520–532.

Khayyam, Khalid Umer, et al. “Pyrazinamide-induced maculopapular rash.” Indian Journal of Dermatology 55.4 (2010): 384.

Njuguna, Christine, et al. “Adverse drug reactions reported to a national HIV & tuberculosis health care worker hotline in South Africa: Description and prospective follow-up of reports.” Drug safety 39.2 (2016): 159–169.

Arbex, Marcos Abdo, et al. “Antituberculosis drugs: drug interactions, adverse effects, and use in special situations-part 1: first-line drugs.” Jornal Brasileiro de Pneumologia 36 (2010): 626–640.

Marra, F., et al. “Adverse drug reactions associated with first-line anti tuberculosis drug regimens.”The International Journal of Tuberculosis and Lung Disease 11.8 (2007): 868–875.

Yee, Daphne, et al. “Incidence of serious side effects from first-line antituberculosis drugs among patients treated for active tuberculosis.” American journal of respiratory and critical care medicine 167.11 (2003): 1472–1477.

Michael, O.S., et al. “Adverse events to first line anti-tuberculosis drugs in patients co-infected with HIV and tuberculosis.” Annals of Ibadan postgraduate medicine 14.1 (2016): 21–29.

Dosumu, E.A. “Side-effects of drugs used in directly observed treatment short-course in newly diagnosed pulmonary tuberculosis subjects in Nigerians: a controlled clinical study.” The Nigerian Postgraduate Medical Journal 9.1 (2002): 34–37.

Hong Kong Chest Service/British Medical Research Council. “Controlled Trial of 6-Month and 8-Month Regimens in the Treatment of Pulmonary Tuberculosis: First Report.” American Review of Respiratory Disease 118.2 (1978): 219–227.

Arbex, Marcos Abdo, et al. “Antituberculosis drugs: drug interactions, adverse effects, and use in special situations-part 1: first-line drugs.” Jornal Brasileiro de Pneumologia 36 (2010): 626–640.

Chhetri, Anupa Khatri, et al. “A study of adverse drug reactions caused by first line anti-tubercular drugs used in Directly Observed Treatment, Short course (DOTS) therapy in western Nepal, Pokhara.” JPMA 58.531 (2008).

Koju, Dinesh, et al. “Occurrence of side effects from anti-tuberculosis drugs in urban Nepalese population under DOTS treatment.” Kathmandu University J Sci Eng Technol 1.1 (2005): 1–2.

Blumberg, Henry M., et al. “American thoracic society/centers for disease control and prevention/infectious diseases society of America: treatment of tuberculosis.” American journal of respiratory and critical care medicine 167.4 (2003): 603.

Baghaei, Parvaneh, et al. “Incidence, clinical and epidemiological risk factors, and outcome of drug-induced hepatitis due to antituberculous agents in new tuberculosis cases.” American journal of therapeutics 17.1 (2010): 17–22.

Carr, Ronald E., and Paul Henkind. “Ocular manifestations of ethambutol: Toxic amblyopia after administration of an experimental antituberculous drug.” Archives of ophthalmology 67.5 (1962): 566–571.

TSAI, RONG-KUNG, and YING-HSUN LEE. “Reversibility of ethambutol optic neuropathy." Journal of ocular pharmacology and therapeutics 13.5 (1997): 473–477.

Tan, W. C., et al. “Two years review of cutaneous adverse drug reaction from first line anti-tuberculous drugs.” Medical Journal of Malaysia 62.2 (2007): 143.


Refbacks

  • There are currently no refbacks.